source
- FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapyThe U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
- Drugmakers urged to assess device capabilities and engage regulators early for combo productsAt the AFDO/RAPS Combination Products Summit, a panel of experts advised drugmakers that developing standalone medical devices to be used with their drugs requires careful evaluation of the devices…